Want to join the conversation?
Generics manufacturer $MYL launches Fluvastin Sodium Extended-release Tablets, 80 mg, in the U.S. for the treatment of patients with hypercholesterolemia and mixed dyslipidemia. The product is the generic equivalent of Novartis' Lescol XL Tablets. Per IMS Health, Lescol generated almost $38MM in U.S. sales in the 12-month period ending June 30.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.